Sara L Zettervall1, Tammy Ju2, Jeremy L Holzmacher, Lisbi Rivas, Paul P Lin, Khashayar Vaziri. 1. Department of Surgery, George Washington University, 2150 Pennsylvania Ave, Suite 6B, Washington, DC, 20037, USA. 2. Department of Surgery, George Washington University, 2150 Pennsylvania Ave, Suite 6B, Washington, DC, 20037, USA. tammyju@gwu.edu.
Abstract
BACKGROUND: Post-operative pancreatic fistulas remain a significant source of morbidity following pancreatic surgery. Few studies have evaluated the effect of neoadjuvant chemotherapy and radiation on this adverse outcome. This study aims to evaluate the effects of neoadjuvant therapy on 30-day morbidity and mortality following pancreaticoduodenectomy. STUDY DESIGN: A retrospective analysis was performed utilizing the targeted pancreas module of the National Surgical Quality Improvement Project (NSQIP) from 2014 to 2015 for patients undergoing pancreaticoduodenectomy with pancreaticojejunal reconstruction. A fistula was defined according to the NSQIP definition. Patient demographics, operative variables, and 30-day outcomes were compared between those who received no neoadjuvant therapy, chemoradiation, chemotherapy alone, and radiation alone. Univariate analysis was completed using chi-square, Fisher exact test, Student's t test, and Mann-Whitney U test where appropriate. Independent predictors of fistula formation were established using multivariable regression. A P value < 0.05 was considered significant. RESULTS: Three thousand one hundred fourteen patients were included of which 559 patients (18%) developed a pancreatic fistula. Two thousand six hundred thirty-five (85%) patients did not undergo neoadjuvant therapy, 207 (6.6%) had chemoradiation, 256 (8.2%) had chemotherapy alone, and 16 (0.5%) had radiation alone. Patients who developed a fistula had increased 30-day mortality (4.9 vs. 1.7%, P < .001) and major morbidities. Following multivariable analysis, neoadjuvant radiation (OR 2.1, 95% CI 1.0-4.5) was associated with increased fistula formation while neoadjuvant chemotherapy (OR 0.5, 95% CI 0.3-0.9) was protective. CONCLUSION: Neoadjuvant chemotherapy provides protection against the development of pancreatic fistulas while neoadjuvant radiation potentiates formation likely due to their effects on the texture of the pancreatic gland. Given the morbidity of pancreatic fistula formation, these factors should be considered in neoadjuvant regimens.
BACKGROUND: Post-operative pancreatic fistulas remain a significant source of morbidity following pancreatic surgery. Few studies have evaluated the effect of neoadjuvant chemotherapy and radiation on this adverse outcome. This study aims to evaluate the effects of neoadjuvant therapy on 30-day morbidity and mortality following pancreaticoduodenectomy. STUDY DESIGN: A retrospective analysis was performed utilizing the targeted pancreas module of the National Surgical Quality Improvement Project (NSQIP) from 2014 to 2015 for patients undergoing pancreaticoduodenectomy with pancreaticojejunal reconstruction. A fistula was defined according to the NSQIP definition. Patient demographics, operative variables, and 30-day outcomes were compared between those who received no neoadjuvant therapy, chemoradiation, chemotherapy alone, and radiation alone. Univariate analysis was completed using chi-square, Fisher exact test, Student's t test, and Mann-Whitney U test where appropriate. Independent predictors of fistula formation were established using multivariable regression. A P value < 0.05 was considered significant. RESULTS: Three thousand one hundred fourteen patients were included of which 559 patients (18%) developed a pancreatic fistula. Two thousand six hundred thirty-five (85%) patients did not undergo neoadjuvant therapy, 207 (6.6%) had chemoradiation, 256 (8.2%) had chemotherapy alone, and 16 (0.5%) had radiation alone. Patients who developed a fistula had increased 30-day mortality (4.9 vs. 1.7%, P < .001) and major morbidities. Following multivariable analysis, neoadjuvant radiation (OR 2.1, 95% CI 1.0-4.5) was associated with increased fistula formation while neoadjuvant chemotherapy (OR 0.5, 95% CI 0.3-0.9) was protective. CONCLUSION: Neoadjuvant chemotherapy provides protection against the development of pancreatic fistulas while neoadjuvant radiation potentiates formation likely due to their effects on the texture of the pancreatic gland. Given the morbidity of pancreatic fistula formation, these factors should be considered in neoadjuvant regimens.
Authors: Raghunandan Venkat; Barish H Edil; Richard D Schulick; Anne O Lidor; Martin A Makary; Christopher L Wolfgang Journal: Ann Surg Date: 2012-06 Impact factor: 12.969
Authors: Claudio Bassi; Giovanni Marchegiani; Christos Dervenis; Micheal Sarr; Mohammad Abu Hilal; Mustapha Adham; Peter Allen; Roland Andersson; Horacio J Asbun; Marc G Besselink; Kevin Conlon; Marco Del Chiaro; Massimo Falconi; Laureano Fernandez-Cruz; Carlos Fernandez-Del Castillo; Abe Fingerhut; Helmut Friess; Dirk J Gouma; Thilo Hackert; Jakob Izbicki; Keith D Lillemoe; John P Neoptolemos; Attila Olah; Richard Schulick; Shailesh V Shrikhande; Tadahiro Takada; Kyoichi Takaori; William Traverso; Charles R Vollmer; Christopher L Wolfgang; Charles J Yeo; Roberto Salvia; Marcus Buchler Journal: Surgery Date: 2016-12-28 Impact factor: 3.982
Authors: Amanda B Cooper; Abhishek D Parmar; Taylor S Riall; Bruce L Hall; Matthew H G Katz; Thomas A Aloia; Henry A Pitt Journal: J Gastrointest Surg Date: 2014-08-05 Impact factor: 3.452
Authors: Andreas Schmid Frymerman; Jochen Schuld; Patrick Ziehen; Otto Kollmar; Christoph Justinger; Marco Merai; Sven Richter; Martin Karl Schilling; Mohammed Reza Moussavian Journal: J Gastrointest Surg Date: 2010-01-22 Impact factor: 3.452
Authors: Keith J Roberts; James Hodson; Homoyoon Mehrzad; Ravi Marudanayagam; Robert P Sutcliffe; Paolo Muiesan; John Isaac; Simon R Bramhall; Darius F Mirza Journal: HPB (Oxford) Date: 2013-11-08 Impact factor: 3.647
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Ayman El Nakeeb; Waleed Askar; Ehab Atef; Ehab El Hanafy; Ahmad M Sultan; Tarek Salah; Ahmed Shehta; Mohamed El Sorogy; Emad Hamdy; Mohamed El Hemly; Ahmed A El-Geidi; Tharwat Kandil; Mohamed El Shobari; Talaat Abd Allah; Amgad Fouad; Mostafa Abu Zeid; Ahmed Abu El Eneen; Nabil Gad El-Hak; Gamal El Ebidy; Omar Fathy; Ahmed Sultan; Mohamed Abdel Wahab Journal: World J Gastroenterol Date: 2017-10-14 Impact factor: 5.742